MultiCell Technologies's total inventories for the quarter that ended in Aug. 2015 was $0.00 Mil. MultiCell Technologies's average total inventories from the quarter that ended in May. 2015 to the quarter that ended in Aug. 2015 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. MultiCell Technologies's Net-Net Working Capital per share for the quarter that ended in Aug. 2015 was $-0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
MultiCell Technologies's Days Inventory for the
three
months ended in Aug. 2015 was 0.00.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MultiCell Technologies's Inventory-to-Revenue for the quarter that ended in Aug. 2015 was 0.00.
MultiCell Technologies (OTCPK:MCET) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
MultiCell Technologies's Net-Net Working Capital Per Share for the quarter that ended in Aug. 2015 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
MultiCell Technologies's Inventory to Revenue for the quarter that ended in Aug. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
MultiCell Technologies Total Inventories Related Terms
MultiCell Technologies Total Inventories Historical Data
* Premium members only.
The historical data trend for MultiCell Technologies's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MultiCell Technologies Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
MultiCell Technologies (MCET) has a Total Inventories of $0.00 Mil as of Aug. 2015. The total amount of inventory as recorded on a company's balance sheet. View historical data for MultiCell Technologies and its competitors.
Is MultiCell Technologies' Total Inventories too high?
MultiCell Technologies' current Total Inventories is $0.00 Mil.
How does MultiCell Technologies' Total Inventories compare to ERGO and OPLI?
MultiCell Technologies' Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for MultiCell Technologies and its competitors. MultiCell Technologies's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MultiCell Technologies stock overvalued right now?
MultiCell Technologies (MCET) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For MultiCell Technologies (MCET), the current Total Inventories is $0.00 Mil as of Aug. 2015. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MultiCell Technologies Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and others. Its therapeutic development platform includes several patented techniques used to isolate, characterize, and differentiate stem cells from the human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company's medical device development platform is based on the design of a next-generation bioabsorbable stent, the Ideal BioStent, for interventional cardiology and peripheral vessel applications. All the operations are functioned within United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MCET has been successfully added to your 